Opus Point Partners Management’s Standard BioTools LAB Stock Holding History

Opus Point Partners Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-45,000	Closed	-$363K	–	50
2016 Q1	$363K	Sell	45,000 -25,000	-36%	-$180K	0.28%	49
2015 Q4	$757K	Buy	70,000 +55,000	+367%	+$540K	0.5%	49
2015 Q3	$122K	Buy	+15,000	New	+$236K	0.07%	56

Other funds holding LAB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

LCS

Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Emerald Acquisition Seattle, Washington $51.8B AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Opus Point Partners Management's LAB Position: Q2 2016 in Review

Opus Point Partners Management sold out of Standard BioTools (LAB) in Q2 2016, closing a stake of 45,000 shares — an estimated $363K sold.

Opus Point Partners Management first reported a position in LAB in Q3 2015 and held it in 3 quarters. The position peaked at $757K in Q4 2015. 97 funds tracked by Wall St. Rank hold LAB as of Q2 2016.

Opus Point Partners Management reported no remaining Standard BioTools position as of Q2 2016 after selling out during the quarter.
Opus Point Partners Management sold 45,000 Standard BioTools shares in Q2 2016, an estimated $363K.
Opus Point Partners Management first reported a position in Standard BioTools in Q3 2015 and held it in 3 quarters.
Opus Point Partners Management's Standard BioTools position peaked at $757K in Q4 2015.
97 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2016.

Based on Opus Point Partners Management's 13F filing for Q2 2016, filed 15 Aug 2016.